Skip to content
  • Facebook
  • Twitter
  • Instagram
  • Email
NEWSX 360 : The Global News Platform

NEWSX 360 : The Global News Platform

News from across the Globe

  • Home
  • About Us
  • Terms & Conditions
  • Contact Us
  • Editor’s Note
  • Privacy Policy
  • Toggle search form
  • SalonSupremo.com launches Cloud Software to S M A R T L Y Manage Salon & Spa Businesses News
  • Silken Velvet Brings Miami and London Vibes to BKC Mumbai News
  • Head-On: Why Should Centres Of Learning Become Centres Of Sexual Harassment? India
  • Digital position printing has a big hand in making Surat a garment hub News
  • BUSINESS EXCELLENCE AWARDS 2024 ORGANISED BY CORPORATE CONNECT News
  • Globe Textiles will add a garment processing capacity of up to 20,000 units per day and 6 Lakh units per month News
  • Diana Penty Arrives At Milan Fashion Week Looking No Less Than A Chic Business Lady In A Pant Suit India
  • Museum on Wheels at Global English School, Diva India

Concept Medical Enrolls First Patient in MAGICAL-SV IDE Trial, Expands Coronary Program Globally

Posted on August 4, 2025 By Team NewsX 360 No Comments on Concept Medical Enrolls First Patient in MAGICAL-SV IDE Trial, Expands Coronary Program Globally

Tampa (Florida) [USA], August 4: Concept Medical Inc., a global pioneer in drug-delivery technologies, today announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first enrollment marks a major milestone in the company’s mission to revolutionize coronary artery disease (CAD) treatment and expands Concept Medical’s clinical program into the United States and Europe.

The first patient was enrolled at Mount Sinai Hospital in New York by Dr. Samin Sharma, Director of Interventional Cardiology, marking a crucial step in advancing treatment options for patients with small-vessel coronary artery disease.

“Today marks a great feat for us and for the MAGICAL-SV trial,” said Dr. Samin Sharma. “My team at Mount Sinai is privileged to be the first to begin this study. This is a proud moment for all of us, especially knowing what the trial signifies and aims to achieve by evaluating MagicTouchas a potential alternative for treating small vessels in the U.S.”

This initial U.S. enrollment follows the FDA’s IDE approval of Concept Medical’s MagicTouch SCB and boosts the company’s broader coronary clinical program. Concept Medical is now actively enrolling in three IDE trials concurrently in the U.S., spanning across coronary and peripheral interventions and underscoring its commitment to bringing innovative therapies to patients worldwide.

MAGICAL-SV is a prospective, multicenter, single-blind randomized trial (2:1 randomization) comparing Concept Medical’s MagicTouch sirolimus-coated balloon to drug-eluting stents (Everolimus eluting stents [EES] or Zotarolimus eluting stents [ZES]) for the treatment of small coronary artery lesions. Randomization is stratified by study site and presence of medically-treated diabetes mellitus status. The trial will enroll 1,605 patients across the U.S. and Europe, to evaluate the primary endpoint of target lesion failure (TLF) at 12 months.

The MAGICAL-SV trial is led by an international team of renowned cardiologists, Dr. Martin B. Leon (USA) serves as Study Chair, with principal investigators (PI) Dr. Azeem Latib (USA), Dr. Ajay Kirtane (USA), and Prof. Antonio Colombo (Europe).

Dr. Azeem Latib, a U.S. PI for MAGICAL-SV, noted, “The first U.S. patient enrollment in the MAGICAL-SV study marks an exciting step forward in building robust evidence for sirolimus-coated balloon technology in the treatment of small-vessel coronary disease. As we explore metal-free PCI strategies, this study brings renewed hope for safer, more effective options for our patients.”

Prof. Antonio Colombo, who leads the European arm of the study, added, “Starting small and going big! MAGICAL-SV represents an important step in building evidence for sirolimus-coated balloons.”

This milestone embodies a “leave nothing behind” philosophy in coronary interventions, treating arterial blockages without permanent implants and addressing the limitations of metallic stents in small vessels. Dr. Martin B. Leon, the Study Chair, emphasized the significance of evaluating a no-stent strategy through this trial: “The initiation of the MAGICAL-SV trial marks an important step in evaluating sirolimus-coated balloon therapy for small coronary vessels. By addressing key limitations of stenting in this complex anatomy, the study aims to generate strong comparative data versus DES. The results could inform future treatment strategies in the U.S. and Europe, offering clinicians a potential alternative for managing small-vessel disease.”

With this pioneering trial, MAGICAL-SV is expected to yield compelling clinical evidence in support of sirolimus-coated balloon therapy. The outcomes will also support Concept Medical’s Pre-Market Approval (PMA) application for the MagicTouch SCB in small-vessel indication, potentially transforming the standard of care in coronary artery disease.

Dr. Manish Doshi, Founder and Managing Director of Concept Medical, said, “At Concept Medical, our unwavering commitment to innovation and patient care drives us to push the boundaries of what is possible in vascular interventions. The initiation of MAGICAL-SV reinforces our dedication to delivering next-generation, evidence-based solutions to clinicians and patients across the globe. Our ultimate goal is to transform the current standard of care and provide better outcomes and quality of life for patients affected by CAD.”

About MagicTouch SCB

MagicTouch SCB is Concept Medical’s sirolimus-coated balloon platform, developed with proprietary Nanoluté technology to deliver sub-micron particles of sirolimus in a biocompatible carrier for deep arterial wall penetration. The device has received CE Mark approval in Europe and a Breakthrough Device designation from the U.S. FDA for small coronary vessels and in-stent restenosis.

About Concept Medical

Concept Medical Inc., headquartered in Tampa, Florida, is a global leader in cutting-edge drug-delivery technologies for cardiovascular interventions. The company is dedicated to improving patient care through research and development of novel drug-delivery platforms engineered to precisely deliver therapeutic agents to diseased vascular tissue. Concept Medical’s MagicTouch family of sirolimus-coated balloons is the world’s first and most widely used SCB technology, recognized for its versatility, safety and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have treated over one million patients worldwide, setting a new benchmark in vascular therapy.

For media inquiries, please contact: pr@conceptmedical.com

Related

Brands

Post navigation

Previous Post: 12th Annual MILT Congress Goa 2025: A Power-Packed Experience That Raised the Bar
Next Post: KRN Heat Exchanger Reports 35% Growth in Net Profit in Q1 FY26

Related Posts

  • India Shines at Global Celebrity League Launch: Stars and Cricketers Set Dubai Stage Ablaze Brands
  • Tower 4 of Paradigm Realty’s Ambitious 71 Downtown Project in Chembur Adds a Luxurious Sparkle to the Festival of Lights Brands
  • Main Aisa Kyun Hoon:The Astrology Series You Didn’t Know You Needed Brands
  • Surat’s First Event Conclave: A Bold Leap That Could Ignite Innovation in Event Industry Brands
  • Ahmedabad to Relish Lost Flavors at Ishaara’s 15-Day Undivided Punjab Pop-Up Menu Brands
  • Suzuki Delivers 125 Access 125 Scooters Together in Surat on Valentine’s Day Brands

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Art of Living
  • Arts
  • Auto & Transportation
  • Automobile
  • Aviation
  • Banking
  • BCA ELECTIONS 2026
  • Bollywood
  • Brands
  • Business
  • Business Technology
  • Commodities
  • Economy
  • Education
  • Energy
  • Entertain­ment & Media
  • Entertainment
  • Entrepreneurs
  • Environment
  • Financial Services & Investing
  • Fitness
  • Gadgets
  • Health
  • Housing & Infrastructure
  • India
  • Information Technology
  • International
  • International Education
  • Investment
  • Lifestyle
  • Narendra Modi
  • News
  • People & Culture
  • Pharma
  • Policy & Public Interest
  • Politics
  • Sports
  • Stock Market
  • Tamilnadu
  • Technology
  • Telecom
  • The Multitaskers: A Series On Entrepreneurship with difference.
  • Travel
  • Uncategorized
  • UNICEF
  • Wellness
  • World News

Recent Posts

  • RoYALS Garba Faces Outrage from Barodians: High Fees, No Parking — Visitors Clash with Security, Horns Blare in Protest as Gates Shut After 10 PM
  • Opposition to ring the Election Commission tomorrow: Congress maps a street-to-Parliament campaign through October and November
  • Cockroach Party to CEC: Quit in 48 Hours — or We Take the Fight Nationwide Over 13 Crore Deleted Voters
  • A Temple of Health and a ₹1-Lakh-Crore Bet: Bengal CM, Gautam Adani Break Ground on 2,000-Bed Arogya Mandir
  • Baroda’s Moliya Captains Rest of India U-23 for CK Nayudu Trophy Clash in Chennai

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • October 2021
  • September 2021

  • Sathlokhar Synergys E&C Global Crosses INR 400 Cr, Records 62 Percent YoY Growth Brands
  • Governor of Telangana Shri Jishnu Dev Varma felicitated by Abhijeeth Bhattacharjee and Pt.Prodyut Mukherjee Brands
  • RMC Switchgears sees over 110% Year-on-Year Growth in H1 Sales for FY 2025–26, driven by strong Solar EPC performance. Brands
  • Falguni Pathak Queen of Dandiya to perform Navratri 2025 at King of Venue Brands
  • OPPO India lights up the festive season with ‘Tum Jagmagao’, celebrating Self-Discovery with Ranbir Kapoor and Jitendra Kumar Brands
  • Gandhi Family Celebrates Maha Ganesh Utsav 2025 with Eco-Friendly ‘Ghar Ka Ganesh’ in Juhu, Mumbai Brands
  • Top 10 Personalities to Watch in 2025 Brands
  • 5 Key Features That Make the TCL Q6CS Series a Smart Choice Brands

Powered by PressBook News WordPress theme